Ginkgo Bioworks Holdings Inc (DNA) Reports Decline in 2023 Revenue Amid Transition and ...
Company Sees Growth in Cell Engineering Services and Advances in Biosecurity Segment
Stay updated with breaking news from Cell Programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company Sees Growth in Cell Engineering Services and Advances in Biosecurity Segment
$251 million of Total revenue in 2023 $139 million in Cell Engineering services revenue, representing 31% growth over 2022 78 new Cell Programs added in 2023, representing 32% growth over 2022 and...
Expects to meet 2023 new program and revenue guidance ranges Ended the year with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as Ginkgo sees...
Wednesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million.
Wednesday, Ginkgo Bioworks Holdings Inc DNA released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million.…